Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

One of the biggest challenges in cancer treatment is addressing the ability of cancer cells to adapt and become resistant, ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with ...

Psychedelic mushrooms, containing the active ingredient psilocybin, have shown remarkable potential in treating various mental health conditions, including treatment-resistant depression. Leading ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

A new treatment being offered by High Plains Mental Health Center is proving to be life-changing for some people suffering ...

TMS services are available at the Hays Main Office of High Plains Mental Health Center, 208 E. Seventh St. For more ...